search
Back to results

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Primary Purpose

Advanced or Metastatic Solid Tumors

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
DCBY02
Sponsored by
DynamiCure Biotechnology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced or Metastatic Solid Tumors

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Selected Inclusion Criteria (Part A and Part B):

Male or female patients ≥ 18 years of age.

Histologically or cytologically confirmed incurable or metastatic solid tumors - colorectal, gastric, non-small cell lung, renal cell, breast, hepatocellular, ovarian, cervical cancer, GBM or with a potential benefit from PD-1/PD-L1 blockade where hypoxia is associated with resistance to PD-1 blockade eg, as reported for or head and neck cancer and is not amenable to curative treatment.

The malignancy must have progressed after at least 1 available standard therapy for incurable disease, and the patient has failed or is intolerant to all available therapies known to be active for the malignancy and have meaningful impact on the disease.

Patients with unresectable or metastatic solid tumors, with the exemption of patients with GBM, must have a lesion that can be biopsied with acceptable clinical risk and agree to have a fresh biopsy at Screening and in the first week of Cycle 2.

At least 1 measurable lesion according to RECIST Version 1.1.

Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

Adequate organ function and bone marrow reserve as indicated by the following laboratory assessments performed within 14 days prior to the first dose of study drug.

For female patients of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test and agree to use highly effective contraception.

For men who are not surgically sterile must agree to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating sperm.

The patient is capable of understanding and complying with the protocol and has signed the required ICF. The appropriate ICF must be signed before relevant study procedures are performed. If applicable, the female partner of a male patient understands and signs the pregnant partner's ICF.

Selected Exclusion Criteria (Part A and Part B):

Treatment with anticancer therapy, including investigational therapy, within 4 weeks prior to the first dose of study drug.

Patients with > Grade 1 AEs (except Grade 2 alopecia or hearing impairment) related to previous treatment with anticancer or investigational therapy that do not resolve.

Systemic arterial thrombotic or embolic events, such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 3 months prior to the first dose of study drug.

Systemic venous thrombotic events (eg, deep vein thrombosis) or pulmonary arterial events (eg, pulmonary embolism) within 1 month prior to the first dose of study drug. Patients with venous thrombotic events prior to the first dose of study drug on stable anticoagulation therapy are eligible.

Left ventricular ejection fraction (LVEF) < 50% or below the lower limit for normal institutional level.

Major surgery within 4 weeks and minor surgery within 2 weeks of the first dose of study drug; following surgeries, all surgical wounds must be healed and free of infection or dehiscence.

The patient has marked proteinuria ≥ 2 g/24 hours and/or nephrotic syndrome. Patients with proteinuria 2+ or greater urine dipstick reading should undergo further assessment, eg, a 24-hour urine collection.

Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.

Known allergy or hypersensitivity to any component of the study drug.

Sites / Locations

  • HonorHealthRecruiting
  • Dana Farber Cancer InstituteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Part 1: Dose Escalation

Part 2: Dose Expansion

Arm Description

Dose escalation to investigate safety, tolerability, and determine recommended phase 2 dose (RP2D) for DCBY02.

Dose expansion to further investigate safety, tolerability, and preliminary evidence of antitumor activity and characterize PK and PD of DCBY02.

Outcomes

Primary Outcome Measures

Incidence of DLTs occurring in the first 28 days following DCBY02 administration
Frequency and severity of treatment-emergent adverse events (TEAEs)
Objective response rate (ORR) as determined per Investigator assessment
Duration of response (DOR) as determined per Investigator assessment
Disease control rate (DCR) as determined per Investigator assessment
Progression free survival (PFS) as determined per Investigator assessment

Secondary Outcome Measures

Objective response rate (ORR) as determined per Investigator assessment
Duration of response (DOR) as determined per Investigator assessment
Disease control rate (DCR) as determined per Investigator assessment
Progression free survival (PFS) as determined per Investigator assessment
Overall survival (OS)
Pharmacokinetic parameters of DCBY02: maximum observed concentration (Cmax)
Pharmacokinetic parameters of DCBY02: area under the concentration-time curve (AUC)
Pharmacokinetic parameters of DCBY02: clearance (CL)
Pharmacokinetic parameters of DCBY02: volume of distribution (Vz)
Pharmacokinetic parameters of DCBY02: half-life (t1/2)
Parts 1A/2A: Incidence of anti-drug antibody (ADA) and neutralizing antibodies (NAbs) against DCBY02

Full Information

First Posted
August 9, 2022
Last Updated
August 25, 2023
Sponsor
DynamiCure Biotechnology
search

1. Study Identification

Unique Protocol Identification Number
NCT05496595
Brief Title
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Official Title
A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 26, 2022 (Actual)
Primary Completion Date
September 2024 (Anticipated)
Study Completion Date
October 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
DynamiCure Biotechnology

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Study DCBY02-101 is a multicenter, open-label, Phase 1 study to assess the effects of anti-CD93 mAb (DCBY02) as a monotherapy in patients with advanced or metastatic solid tumors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced or Metastatic Solid Tumors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
108 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part 1: Dose Escalation
Arm Type
Experimental
Arm Description
Dose escalation to investigate safety, tolerability, and determine recommended phase 2 dose (RP2D) for DCBY02.
Arm Title
Part 2: Dose Expansion
Arm Type
Experimental
Arm Description
Dose expansion to further investigate safety, tolerability, and preliminary evidence of antitumor activity and characterize PK and PD of DCBY02.
Intervention Type
Drug
Intervention Name(s)
DCBY02
Intervention Description
A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
Primary Outcome Measure Information:
Title
Incidence of DLTs occurring in the first 28 days following DCBY02 administration
Time Frame
2 years
Title
Frequency and severity of treatment-emergent adverse events (TEAEs)
Time Frame
From first dose to Cycle 2 Day 8 (28 days)
Title
Objective response rate (ORR) as determined per Investigator assessment
Time Frame
1 year
Title
Duration of response (DOR) as determined per Investigator assessment
Time Frame
1 year
Title
Disease control rate (DCR) as determined per Investigator assessment
Time Frame
1 year
Title
Progression free survival (PFS) as determined per Investigator assessment
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Objective response rate (ORR) as determined per Investigator assessment
Time Frame
1 year
Title
Duration of response (DOR) as determined per Investigator assessment
Time Frame
1 year
Title
Disease control rate (DCR) as determined per Investigator assessment
Time Frame
1 year
Title
Progression free survival (PFS) as determined per Investigator assessment
Time Frame
1 year
Title
Overall survival (OS)
Time Frame
1 year
Title
Pharmacokinetic parameters of DCBY02: maximum observed concentration (Cmax)
Time Frame
2 years
Title
Pharmacokinetic parameters of DCBY02: area under the concentration-time curve (AUC)
Time Frame
2 years
Title
Pharmacokinetic parameters of DCBY02: clearance (CL)
Time Frame
2 years
Title
Pharmacokinetic parameters of DCBY02: volume of distribution (Vz)
Time Frame
2 years
Title
Pharmacokinetic parameters of DCBY02: half-life (t1/2)
Time Frame
2 years
Title
Parts 1A/2A: Incidence of anti-drug antibody (ADA) and neutralizing antibodies (NAbs) against DCBY02
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Selected Inclusion Criteria: Male or female patients ≥ 18 years of age. Histologically or cytologically confirmed incurable or metastatic solid tumors - colorectal, gastric, non-small cell lung, renal cell, breast, hepatocellular, ovarian, cervical cancer, GBM or with a potential benefit from PD-1/PD-L1 blockade where hypoxia is associated with resistance to PD-1 blockade eg, as reported for or head and neck cancer and is not amenable to curative treatment. The malignancy must have progressed after at least 1 available standard therapy for incurable disease, and the patient has failed or is intolerant to all available therapies known to be active for the malignancy and have meaningful impact on the disease. Patients with unresectable or metastatic solid tumors, with the exemption of patients with GBM, must have a lesion that can be biopsied with acceptable clinical risk and agree to have a fresh biopsy at Screening and in the first week of Cycle 2. At least 1 measurable lesion according to RECIST Version 1.1. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. Adequate organ function and bone marrow reserve as indicated by the following laboratory assessments performed within 14 days prior to the first dose of study drug. For female patients of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test and agree to use highly effective contraception. For men who are not surgically sterile must agree to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating sperm. The patient is capable of understanding and complying with the protocol and has signed the required ICF. The appropriate ICF must be signed before relevant study procedures are performed. If applicable, the female partner of a male patient understands and signs the pregnant partner's ICF. Selected Exclusion Criteria: Treatment with anticancer therapy, including investigational therapy, within 14 days before the first dose of study drug or 5 half-lives, whichever is shorter. Patients with second malignancy within the previous 3 years, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, cervical carcinoma in situ, resected colorectal adenomatous polyps, breast cancer in situ, or other malignancy for which the patient is not on active anticancer therapy. Patients with known active central nervous system (CNS) metastases. Systemic arterial thrombotic or embolic events, such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 3 months prior to the first dose of study drug. Systemic venous thrombotic events (eg, deep vein thrombosis) or pulmonary arterial events (eg, pulmonary embolism) within 1 month prior to the first dose of study drug. Patients with venous thrombotic events prior to the first dose of study drug on stable anticoagulation therapy are eligible. Left ventricular ejection fraction (LVEF) < 50% or below the lower limit for normal institutional level. Major surgery within 4 weeks and minor surgery within 2 weeks of the first dose of study drug; following surgeries, all surgical wounds must be healed and free of infection or dehiscence. The patient has marked proteinuria ≥ 2 g/24 hours and/or nephrotic syndrome. Patients with proteinuria 2+ or greater urine dipstick reading should undergo further assessment, eg, a 24-hour urine collection. Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks. Known allergy or hypersensitivity to any component of the study drug.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sr Medical Director
Phone
+1 (781) 373-9136
Email
alejandrogomez@dynamicure.com
Facility Information:
Facility Name
HonorHealth
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85258
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Gordon, MD
Facility Name
Dana Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephen Hodi, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

We'll reach out to this number within 24 hrs